PLX
Protalix BioTherapeutics, Inc.Company with tickers: PLX
CIK
1006281
CUSIP
74365A309
Shares Outstanding
80,571,642
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $33,750,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | $4,127,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $5,426,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Operating Income | $21,146,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Net Income | $18,317,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| EPS (Basic) | $0.23 | USD/shares | 2026-03-31 | 10-Q | 2026-05-13 |
| EPS (Diluted) | $0.22 | USD/shares | 2026-03-31 | 10-Q | 2026-05-13 |